Şenocak Taşçı, E. Et Al. 2022. Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study . ASCO GI , (California, United States Of America), 1.

Şenocak Taşçı, E., Oyan, B., & Sönmez, Ö., (2022). Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study . ASCO GI (pp.1). California, United States Of America

Şenocak Taşçı, Elif, BAŞAK OYAN ULUÇ, And ÖZLEM SÖNMEZ. "Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study ," ASCO GI, California, United States Of America, 2022

Şenocak Taşçı, Elif Ş. Et Al. "Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study ." ASCO GI , California, United States Of America, pp.1, 2022

Şenocak Taşçı, E. Oyan, B. And Sönmez, Ö. (2022) . "Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study ." ASCO GI , California, United States Of America, p.1.

@conferencepaper{conferencepaper, author={Elif Şenocak Taşçı Et Al. }, title={Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastaic colorectal cancer : A Turkısh oncology group study }, congress name={ASCO GI}, city={California}, country={United States Of America}, year={2022}, pages={1} }